The Journey of Tamoxifen

Tamoxifen is well absorbed orally with absolute bioavailability
of approximately 100% — essentially no hepatic first-pass loss of the parent drug. Peak plasma
concentrations are reached within 4-7 hours after oral dosing. The drug is available as 10 mg and
20 mg tablets; the standard adjuvant dose is 20 mg once daily. Food slightly affects the rate but
not the extent of absorption. Tamoxifen is highly lipophilic (logP ~6.7) and slowly redistributes
from tissues, contributing to a very long effective duration of action. Multiple metabolic pathways
generate several pharmacologically relevant species, meaning that the therapeutic effect of
tamoxifen is a composite of the parent drug and its metabolites — with endoxifen (4-hydroxy-N-
desmethyl-tamoxifen) being the most pharmacologically critical due to its ~100-fold greater ER
affinity compared to tamoxifen. Steady-state plasma concentrations of tamoxifen and metabolites
are achieved after 4-8 weeks of daily dosing.

Tamoxifen distributes very extensively with a volume of distribution
of approximately 20-50 L/kg, reflecting massive tissue sequestration. Plasma protein binding is
very high at >99% (albumin and alpha-1-acid glycoprotein), but the extensive tissue distribution
means that much of the drug is protein-bound in tissue compartments. Tissue concentrations in the
breast, uterus, liver, and lung greatly exceed plasma concentrations — concentrations in normal
breast tissue and breast tumors may be 10-60-fold above plasma. This tissue accumulation underlies
the very long elimination half-life and provides sustained ER occupancy in the breast. The drug
distributes into breast milk and crosses the placenta; it is teratogenic (category D) and
contraindicated in pregnancy. Tamoxifen achieves brain concentrations approximately equal to plasma,
contributing to neuropsychiatric adverse effects (cognitive complaints, mood changes).

Tamoxifen and its active metabolites are selective estrogen receptor
modulators (SERMs). Estrogen receptors (ER-alpha and ER-beta, encoded by ESR1 and ESR2) are nuclear
receptors that when activated by estradiol recruit specific coactivators (SRC-1, SRC-2, SRC-3) via
the activation function 2 (AF2) domain, activating transcription of proliferative genes (cyclin D1,
c-myc, BCL-2, VEGF) in breast cancer cells. Tamoxifen (and endoxifen) bind ER at the same site as
estradiol but induce a distinct receptor conformation that favors corepressor (SMRT, NCoR) rather than
coactivator binding — making tamoxifen an antagonist in ER-alpha-rich breast tissue. In bone and
cardiovascular tissue (ER-beta predominant), the same SERM conformation recruits coactivators and
acts as a partial agonist (beneficial for bone density preservation). In endometrial tissue (ER-alpha),
tamoxifen acts as a partial agonist — increasing risk of endometrial hyperplasia and uterine
cancer (~2-fold increased risk with 5+ years use). Endoxifen's ~100-fold higher ER affinity
relative to tamoxifen makes it the primary driver of therapeutic effect.

Tamoxifen undergoes extensive multi-pathway hepatic metabolism.
CYP2D6 N-demethylates tamoxifen to N-desmethyl-tamoxifen and then hydroxylates to endoxifen (the
most potent active metabolite). CYP3A4/CYP3A5 convert tamoxifen to N-desmethyl-tamoxifen (less
important pathway to endoxifen), while CYP2D6 and CYP3A4 also produce 4-hydroxy-tamoxifen (4-OH-TAM;
100× more potent than tamoxifen at ER but rapidly glucuronidated and sulfated). The critical clinical
implication: CYP2D6 poor metabolizers (carrying *4, *5, *6, *41 alleles — approximately 7-10%
of Caucasians) produce substantially less endoxifen (3-4-fold lower steady-state concentrations),
which is associated with reduced clinical benefit and increased recurrence risk. Concurrent strong
CYP2D6 inhibitors (paroxetine, fluoxetine — commonly used antidepressants) reduce endoxifen levels
equivalently, with clinical outcome data suggesting worse breast cancer recurrence with this combination.

Tamoxifen and its metabolites are excreted predominantly in feces
via biliary excretion following hepatic conjugation (glucuronidation, sulfation). Urinary excretion
accounts for <20% of the dose. Tamoxifen undergoes enterohepatic recirculation — deconjugated
metabolites reabsorbed from the gut return to systemic circulation, prolonging drug exposure.
The elimination half-life of tamoxifen is 5-7 days; N-desmethyl-tamoxifen 13-14 days; endoxifen
27-75 hours. Steady-state requires 4-8 weeks. After stopping tamoxifen, drug and active metabolites
remain measurable for months due to tissue sequestration and enterohepatic cycling — with potential
for persistent ER blockade for several weeks. Renal impairment does not significantly alter
tamoxifen pharmacokinetics. Hepatic impairment reduces tamoxifen metabolism, potentially increasing
toxicity.

Tamoxifen reduces breast cancer recurrence by approximately 40% and
breast cancer mortality by approximately 30% in ER-positive disease (EBCTCG meta-analysis). Five
years of adjuvant tamoxifen is standard; the ATLAS trial showed that 10 years of therapy provides
additional recurrence reduction particularly in years 10-14. The uterine cancer risk (approximately
2-fold in premenopausal; higher in postmenopausal women) necessitates annual gynecological evaluation.
Thromboembolic events (DVT, PE, stroke) are increased with tamoxifen — particularly in high-risk
women. Hot flashes, vaginal dryness, and mood changes are common quality-of-life issues. Aromatase
inhibitors (letrozole, anastrozole, exemestane) are preferred over tamoxifen in postmenopausal
women due to superior efficacy; tamoxifen remains the standard for premenopausal breast cancer
(aromatase inhibitors require ovarian suppression in this context).